ActoGeniX received EUR 3.07 million, or approximately $4.2 million, from the Flanders government through IWT (Institute for Promotion of Innovation by Science and Technology in Flanders). The funding will allow the company to advance programs based on TopAct™, a platform for oral, targeted delivery of biopharmaceuticals.
ActoGeniX currently is preparing to take its lead compound into Phase II testing in Crohn´s disease and ulcerative colitis. These studies are anticipated to start during the first half of next year. Other programs that will also benefit from the IWT award are therapeutics for treatment of mucositis, celiac disease, diabetes, and obesity, which are at various stages of preclinical discovery and development.